265 related articles for article (PubMed ID: 35157042)
1. Predictors of rapidly progressive interstitial lung disease and mortality in patients with autoantibodies against melanoma differentiation-associated protein 5 dermatomyositis.
So J; So H; Wong VT; Ho R; Wu TY; Wong PC; Tam LH; Ho C; Lam TT; Chung YK; Li WL; To CH; Lau CS; Mok CC; Tam LS
Rheumatology (Oxford); 2022 Nov; 61(11):4437-4444. PubMed ID: 35157042
[TBL] [Abstract][Full Text] [Related]
2. Different Multivariable Risk Factors for Rapid Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis and Anti-Synthetase Syndrome.
Zuo Y; Ye L; Chen F; Shen Y; Lu X; Wang G; Shu X
Front Immunol; 2022; 13():845988. PubMed ID: 35320936
[TBL] [Abstract][Full Text] [Related]
3. Predictors of rapidly progressive interstitial lung disease and prognosis in Chinese patients with anti-melanoma differentiation-associated gene 5-positive dermatomyositis.
Li M; Zhao X; Liu B; Zhao Y; Li X; Ma Z; Yang Q
Front Immunol; 2023; 14():1209282. PubMed ID: 37691917
[TBL] [Abstract][Full Text] [Related]
4. [Clinical characteristics and prognostic factors of patients with anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis associated interstitial lung disease].
Zou RY; Zhao Q; Tian YQ; Yan X; Qiu XH; Gao YJ; Liu Y; Huang M; Cao M; Dai JH; Cai HR
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Aug; 46(8):781-790. PubMed ID: 37536988
[No Abstract] [Full Text] [Related]
5. Rapidly progressive interstitial lung disease risk prediction in anti-MDA5 positive dermatomyositis: the CROSS model.
Wang L; Lv C; You H; Xu L; Yuan F; Li J; Wu M; Zhou S; Da Z; Qian J; Wei H; Yan W; Zhou L; Wang Y; Yin S; Zhou D; Wu J; Lu Y; Su D; Liu Z; Liu L; Ma L; Xu X; Zang Y; Liu H; Ren T; Liu J; Wang F; Zhang M; Tan W
Front Immunol; 2024; 15():1286973. PubMed ID: 38361940
[TBL] [Abstract][Full Text] [Related]
6. Comparison of characteristics and anti-MDA5 antibody distribution and effect between clinically amyopathic dermatomyositis and classic dermatomyositis: a retrospective case-control study.
Ji Q; Pan W; Zhang D; Hou Y; Wang Z
Front Immunol; 2023; 14():1237209. PubMed ID: 38098481
[TBL] [Abstract][Full Text] [Related]
7. Predictors of Poor Outcome of Anti-MDA5-Associated Rapidly Progressive Interstitial Lung Disease in a Chinese Cohort with Dermatomyositis.
Li Y; Li Y; Wu J; Miao M; Gao X; Cai W; Shao M; Zhang X; Xu Y; Cong L; He J; Sun X
J Immunol Res; 2020; 2020():2024869. PubMed ID: 33299896
[TBL] [Abstract][Full Text] [Related]
8. Hypouricemia as a novel predictor of mortality in anti-MDA5 positive dermatomyositis patients with ILD: A retrospective cohort study.
Liu H; Chen B; Guo Y; Liu H; Ran J; Liu R; Yin G; Xie Q
Respir Med; 2024 Feb; 222():107530. PubMed ID: 38228214
[TBL] [Abstract][Full Text] [Related]
9. Elevated serum B-cell activator factor levels predict rapid progressive interstitial lung disease in anti-melanoma differentiation associated protein 5 antibody positive dermatomyositis.
Shi Y; You H; Liu C; Qiu Y; Lv C; Zhu Y; Xu L; Wang F; Zhang M; Tan W
Orphanet J Rare Dis; 2024 Apr; 19(1):170. PubMed ID: 38637830
[TBL] [Abstract][Full Text] [Related]
10. Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review.
Huang K; Vinik O; Shojania K; Yeung J; Shupak R; Nimmo M; Avina-Zubieta JA
Rheumatol Int; 2019 Nov; 39(11):1971-1981. PubMed ID: 31375890
[TBL] [Abstract][Full Text] [Related]
11. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis.
Sakamoto S; Okamoto M; Kaieda S; Fujimoto K; Nagata S; Tominaga M; Nakamura M; Zaizen Y; Nouno T; Koga T; Kawayama T; Kuwana M; Ida H; Hoshino T
Respir Investig; 2018 Nov; 56(6):464-472. PubMed ID: 30150008
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for mortality in patients with anti-MDA5 antibody-positive dermatomyositis: A meta-analysis and systematic review.
Xie H; Zhang D; Wang Y; Shi Y; Yuan Y; Wang L; Fan J; Tian X; Wang J
Semin Arthritis Rheum; 2023 Oct; 62():152231. PubMed ID: 37348186
[TBL] [Abstract][Full Text] [Related]
13. Coexistence of Anti-Ro52 Antibodies in Anti-MDA5 Antibody-Positive Dermatomyositis Is Highly Associated With Rapidly Progressive Interstitial Lung Disease and Mortality Risk.
Lv C; You H; Xu L; Wang L; Yuan F; Li J; Wu M; Zhou S; Da Z; Qian J; Wei H; Yan W; Zhou L; Wang Y; Yin S; Zhou D; Wu J; Lu Y; Su D; Liu Z; Liu L; Ma L; Xu X; Zang Y; Liu H; Ren T; Wang F; Zhang M; Tan W
J Rheumatol; 2023 Feb; 50(2):219-226. PubMed ID: 35705235
[TBL] [Abstract][Full Text] [Related]
14. Proteomic profiling identifies SPP1 associated with rapidly progressive interstitial lung disease in anti-MDA5-positive dermatomyositis.
Qiu Y; Feng X; Liu C; Shi Y; Xu L; You H; Wang L; Lv C; Wang F; Tan W
Arthritis Res Ther; 2024 Jan; 26(1):9. PubMed ID: 38167532
[TBL] [Abstract][Full Text] [Related]
15. Characteristics and prognostic implications of peripheral blood lymphocyte subsets in patients with anti-MDA5 antibody positive dermatomyositis-interstitial lung disease.
Ren FP; Chen Q; Yao SS; Feng L; Xue XY; Zhao WC; Wang D; Zhao ZL; Gu SW; Li T; Shen YW; Gao L; Zang XL; Bao XY; Tong ZH
BMC Pulm Med; 2023 Oct; 23(1):411. PubMed ID: 37898737
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of natural killer cell depletion in predicting progressive fibrosing interstitial lung disease in idiopathic inflammatory myopathies.
Shao C; Xia N; Zhen Y; Zhang X; Yan N; Guo Q
Front Immunol; 2024; 15():1404828. PubMed ID: 38745647
[TBL] [Abstract][Full Text] [Related]
17. Interstitial Lung Disease in Dermatomyositis Without Myositis-Specific and Myositis-Associated Autoantibodies: Study of a Series of 72 Patients From a Single Cohort.
Chen F; Wang J; Zhang P; Zuo Y; Ye L; Wang G; Shu X
Front Immunol; 2022; 13():879266. PubMed ID: 35603153
[TBL] [Abstract][Full Text] [Related]
18. Serum Krebs von den Lungen-6 concentrations reflect severity of anti-melanoma differentiation-associated protein 5 antibody positive dermatomyositis associated interstitial lung disease.
Zhu Y; Wang L; Sun Y; Wang J; Lv C; You H; Xu L; Wang F; Zhang M; Tan W; Ke Y
Clin Exp Rheumatol; 2022 Feb; 40(2):292-297. PubMed ID: 34874831
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis.
Zuo Y; Ye L; Liu M; Li S; Liu W; Chen F; Lu X; Gordon P; Wang G; Shu X
Rheumatology (Oxford); 2020 Oct; 59(10):2829-2837. PubMed ID: 32065646
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
